Your browser doesn't support javascript.
The arrival of SARS-CoV-2-neutralizing antibodies in a currently available commercial immunoglobulin.
Miller, Aaron L; Rider, Nicholas L; Pyles, Richard B; Judy, Barbara; Xie, Xuping; Shi, Pei-Yong; Ksiazek, Thomas G.
  • Miller AL; Assay Development Service Division, Galveston National Laboratory, University of Texas Medical Branch, Galveston, Tex; Department of Pediatrics, University of Texas Medical Branch, Galveston, Tex. Electronic address: aamiller@utmb.edu.
  • Rider NL; Division of Immunology, Allergy and Retrovirology, William T. Shearer Center for Immunobiology, Texas Children's Hospital, Houston, Tex.
  • Pyles RB; Assay Development Service Division, Galveston National Laboratory, University of Texas Medical Branch, Galveston, Tex; Department of Pediatrics, University of Texas Medical Branch, Galveston, Tex.
  • Judy B; Department of Pathology, University of Texas Medical Branch, Galveston, Tex.
  • Xie X; Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, Tex.
  • Shi PY; Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, Tex.
  • Ksiazek TG; Department of Pathology, University of Texas Medical Branch, Galveston, Tex.
J Allergy Clin Immunol ; 149(6): 1958-1959, 2022 06.
Article in English | MEDLINE | ID: covidwho-1799884
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Limits: Humans Language: English Journal: J Allergy Clin Immunol Year: 2022 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Limits: Humans Language: English Journal: J Allergy Clin Immunol Year: 2022 Document Type: Article